Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study
Affiliation:
1. Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt
Abstract
Background:
IDX-184 is a guanosine derivative having a potent inhibitory performance
against HCV NS5b polymerase.
Objective:
To test three different groups of 2'C - modified analogues of guanosine nucleotide
against HCV polymerase.
Method:
Using combined Quantitative Structure-Activity Relationships (QSAR) and molecular
docking, the suggested compounds are studied.
Results:
Examining the docked structures of the compounds with experimentally solved NS5b
structure (PDB ID: 2XI3) revealed that most of the compounds have the same mode of interaction
as that of guanosine nucleotide and hence, NS5b inhibition is possible.
Conclusion:
It is revealed that sixteen modifications have a better binding affinity to NS5b compared
to guanosine. In addition, seven more compounds are better in NS5b binding compared to
the approved drug, sofosbuvir, and the compound under clinical trials, IDX-184. Hence, these
compounds could be potent HCV NS5b inhibitors.
Summary Points:
Novel guanosine modifications were introduced in silico and optimized using
QM. QSAR and docking calculations are performed to test the binding affinity of the compounds
to HCV NS5b active site. Comparison between the binding affinities and the mode of interactions
of the compounds and both GTP and IDX-184 is performed. Structural mining to quantify the
mode of binding of the compounds to NS5b active site pocket.
Publisher
Bentham Science Publishers Ltd.
Reference33 articles.
1. Halfon P, Locarnini S. J Hepatol, Hepatitis C virus resistance to protease inhibitors.,, 2011, 55,, 192-206, 2. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, Rapicetta M. J Clin Microbiol, Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis.,, 2005, 43,, 1902-1909, 3. Bahgat MM, Ibrahim AA, Abd-Elshafy DN, Mesalam AA, Gewaid HE, Ismaeil AA, El-Waseef AM, Maghraby AS, Barakat AB, El-Far MA, Ghanem Hel D, Mohamed AM, Ali MA. Arch Virol, Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate.,, 2009, 154,, 1649-1657, 4. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Curr Opin Virol, Anti-HCV drugs in the pipeline.,, 2011, 1,, 607-616, 5. Das D, Hong J, Chen SH, Wang G, Beigelman L, Seiwert SD, Buckman BO. Bioorg Med Chem, Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.,, 2011, 19,, 4690-4703,
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|